Kyverna Secures $367M in Funding to Advance Breakthrough Cell Therapies for Autoimmune Diseases

We are thrilled to announce that Kyverna has successfully raised $367 million in a Series B funding round led by prominent venture capital firms and strategic investors. As a clinical-stage biopharmaceutical company dedicated to transforming the treatment landscape for patients suffering from autoimmune diseases, this significant investment underscores the confidence our partners have in our innovative approach to cell therapies. Our lead product candidate, KYV-101, is progressing through pivotal clinical trials addressing critical conditions such as stiff-person syndrome, multiple sclerosis, and myasthenia gravis, along with systemic sclerosis and lupus nephritis. With this funding, we aim to accelerate our clinical development programs, further validating our pioneering next-generation chimeric antigen receptor (CAR) T-cell therapies designed to target B-cell-driven autoimmune diseases. This strategic capital will allow us to expand our research and development efforts, with the goal of bringing new, life-changing therapies to patients in need. We appreciate the support from our investors and look forward to advancing Kyverna's mission of delivering patient-centered solutions and making a meaningful impact in the lives of those affected by autoimmune disorders. This funding marks a pivotal moment in our journey, empowering us to develop groundbreaking therapies that can fundamentally reshape patient care in rheumatology and neurology. Stay tuned for more updates as we continue on this exciting path towards innovation in biopharma.